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Clinical significance of ventricular 
fibrillation-flutter induced by ventricular 
programmed stimulation 
Two hundred twenty-four patients underwent ventricular programmed stimulation (VPS) without 
prior documentation of the clinical occurrence of sustained ventricular tachycardia (VT) or 
ventricular fibrillation-flutter (VF). Indications for VPS were: palpitations or nonsustained VT 
during ambulatory monitoring (85 patients), syncope or presyncope (137 patients), and a family 
history of sudden death (two patients). Sustained VF requiring transthoracic defibrillation was 
initiated by VPS in 18 patients (8.0%). Four patients were treated for inducible VF with 
antiarrhythmic agents directed by electropharmacologic testing; five patients were treated 
empirically; nine patients received no therapy. No patient has had a cardiac arrest or sudden 
death during a follow-up period of 25.2 + 13.8 months (mean f  standard deviation). VF was 
initiated by two ventricular extrastimuli in three patients and by three extrastimuli in 15 patients. 
The incidence of VF was similar in patients with and without previous symptoms (8.8% vs 6.9%) 
or heart disease (7.1% vs g.S%). It was significantly higher when VPS at three ventricular sites 
with a current of 5 mA (pulse width 2 msec) was compared to programmed stimulation at two 
ventricular sites with a current twice diastolic threshold (pulse width 2 msec) (15.2% vs 3.0%, 
p < 0.05). VF initiated by VPS in patients without prior VT or VF appears to be a nonspecific 
finding. Antiarrhythmic therapy for VF may not be necessary in these patients. (AM HEART J 
lOg:g5g, 1985.) 
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The clinical significance of ventricular tachycardia 
(VT) induced by ventricular programmed stimula- 
tion (VPS) is well described.‘m5 However, there are 
little data concerning the prognosis for patients in 
whom sustained ventricular ‘fibrillation-flutter (VF) 
is initiated during electrophysiologic testing. A low 
incidence of VF has been reported by several 
authors.6-10 Spielman et al.6 have reported a 3.3% 
incidence of VF during VPS in patients with prior 
documented or suspected VT or VF. They observed 
a subsequent clinical recurrence of VF in the major- 
ity of these patients despite antiarrhythmic therapy 
directed by electropharmacologic testing, and sug- 
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gested that VF initiated by VPS occurs primarily in 
those patients in whom it has previously occurred or 
in whom it will occur spontaneously.6 More recent 
studies have questioned the significance of induced 
VF, noting that its initiation and incidence may 
depend on factors such as the number of premature 
stimuli required and the current strength used 
during VPS.7-g We therefore analyzed the data from 
224 consecutive patients within a clinical history of 
VT or VF who underwent VPS in order to determine 
the clinical significance of induced VF in this group 
of patients. 
METHODS 
Population tested. Two hundred twenty-four patients 
who underwent electrophysiologic testing were evaluated. 
Seventy-seven patients had coronary artery disease, with 
a history of myocardial infarction in 49 patients. Eighteen 
patients had mitral valve prolapse, 14 patients had mitral 
regurgitation or aortic insufficiency, 26 patients had dilat- 
ed cardiomyopathy, four patients had nonobstructive 
hypertrophic cardiomyopathy, one patient had sarcoid 
heart disease, and one patient had corrected transposition 
of the great vessels. Eighty-three patients had no clinical 
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Fig. 1. Ventricular fibrillation-flutter (VF) initiated with three extrastimuli following ventricular 
overdrive pacing of the right ventricular outflow tract. From top to bottom are electrocardiographic leads 
V,, I and III, an intracardiac electrogram from the right ventricular outflow tract (RVOT), and arterial 
blood pressure (BP) recorded on a scale of 0 to 200 mm Hg. The VF cycle length is 180 to 200 msec. The 
QRS complexes and the intraventricular electrograms are polymorphous, and the intraventricular 
electrograms are fractionated. 
evidence of heart disease. Indications for VPS in this 
group of patients were: palpitations or prior nonsustained 
VT (85 patients), unexplained syncope (112 patients), 
presyncope (25 patients), and family history of sudden 
death (two patients). No patient demonstrated a prolong- 
ed QT interval or preexcitation. 
For the purpose of this analysis, VF was defined as 
having a cycle length of 1200 msec and being polymor- 
phous (Fig. 1). Sustained VF was defined as having a 
duration of 230 seconds or requiring defibrillation due to 
circulatory collapse and loss of consciousness. Cases in 
which VF was initiated by ventricular overdrive pacing 
during sustained VT, or in which unimorphic VT sponta- 
neously degenerated into VF, were not included in this 
analysis. 
Electrophysiotogic studies. Electrophysiologic studies 
were performed in the nonsedated, postabsorptive state 
after informed consent was obtained. Antiarrhythmic 
therapy was discontinued for a minimum of 4 half-lives 
prior to VPS. Two or three quadripolar or bipolar cathe- 
ters were inserted percutaneously and were positioned in 
the heart under fluoroscopic guidance. The number of 
recording sites varied, but usually included the high right 
atrium, the His bundle electrogram, the right ventricular 
apex, and/or the left ventricular apex. Ventricular stimu- 
lation was performed using a programmable stimulator 
and an isolated constant current source (Bloom Asso- 
ciates, Ltd., Reading, Pa.). 
Our stimulation protocol evolved over the 4.5 years of 
this study. One hundred eighteen patients underwent 
stimulation at one right and one left ventricular site with a 
current twice diastolic threshold (pulse width 2 msec). 
The next 106 patients underwent stimulation at two right 
ventricular sites and at one left ventricular site with a 
fixed current of 5 mA (pulse width 2 msec). Left ventric- 
ular stimulation was not performed if sustained VT’was 
induced during right VPS or if there was a contraindica- 
tion to left ventricular stimulation. 
Our protocol for VPS has been described previously.” 
Ventricular overdrive pacing was performed initially at 
the right ventricular apex at cycle lengths of 600 to 250 
msec. Ventricular programmed stimulation was then per- 
formed at one or two drive cycle lengths (500 msec, or 500 
and 400 msec) using one, two, and three extrastimuli. If 
VT or VF was not initiated, the next ventricular site was 
then stimulated in a similar fashion. The protocol was 
continued until VT or VF with a duration of 230 seconds 
or circulatory collapse was initiated, or until nonsus- 
tained, polymorphus VT having a cycle length 5210 msec 
and a duration ~10 seconds was initiated at least twice. 
During electropharmacologic testing, the same protocol 
used during baseline study was repeated following acute 
IV drug administration to determine t,herapeutic efficacy. 
Acute electropharmacologic testing was performed in 15 
of 18 cases in which sustained VF was initiated, using 
procainamide (20 mg/kg), propranolol (0.2 mg/kg), or 
encainide (0.9 mg/kg). Chronic antiarrhythmic therapy 
was determined by the individual preferences of each 
patient and the referring physician. Statistical analysis 
was performed using the paired t test. 
RESULTS 
Inducible VF. Eighteen of 224 patients (8.0%) had 
inducible sustained VF. All patients required trans- 
thoracic, direct-current defibrillation with 200 to 
400 J due to circulatory collapse and loss of con- 
sciousness. Four patients received chronic antiar- 
rhythmic treatment based on electropharmacologic 
testing (three with propranolol, one with procain- 
amide). Five patients were treated empirically 
(three with amiodarone, one with flecainide, and one 
with procainamide and quinidine); nine patients 
received no therapy. Five of 10 patients with heart 
disease (50%) and four of eight patients without 
heart disease (50%) were treated. Five of 12 symp- 
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Table I. Clinical characteristics and results of therapy in 16 patients with ventricular fibrillation-flutter induced by 
ventricular programmed stimulation 
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Abbreviations: A = amiodarone; AI = aortic insufficiency; CAD = coronary artery disease; CM = cardiomyopathy; F = female; Fl = flecainide; I = propran- 
olol; IMI = remote, inferior myocardial infarction; M = male; MVP = mitral valve prolapse; no. = number; NOAH = nonobstructive, asymmetric 
hypertrophy; NSVT = nonsustained ventricular tachycardia; P = procainamide; Q = quinidine; SVT = supraventricular tachycardia; VPD = single, 
premature ventricular depolarizations; VSD = ventricular septal defect. 
tomatic patients (42 % ) with syncope/presyncope 
and four of six (67 % ) without syncope/presyncope 
were treated. No patient has had cardiac arrest or 
sudden death during a follow-up period of 25.2 + 
13.8 months (mean + standard deviation). 
Patient characteristics. The clinical characteristics 
of these 18 patients were as follows (Table I). There 
were 12 men and 6 women with a mean age of 
52 f 18 years (+ standard deviation). Ten of these 
18 patients had clinical evidence of structural heart 
disease. Three patients had coronary artery disease 
with one patient having had a remote myocardial 
infarction; three patients had mitral valve prolapse; 
two had an idiopathic congestive cardiomyopathy, 
one had aortic valvular insufficiency, and one had 
nonobstructive asymmetric hypertrophy. The 
remaining eight patients had no clinical evidence of 
structural heart disease. The indications for VPS in 
this group were: unexplained syncope (11 patients) 
or presyncope (one patient), and evaluation of non- 
sustained VT (five patients). One additional patient 
(case No. 3), who had no clinical evidence of heart 
disease and who was asymptomatic, was studied 
after her monozygotic twin sister died suddenly. 
Prior to VPS, five patients had had nonsustained 
VT and 13 patients had had either single premature 
ventricular depolarizations or no arrhythmia noted 
during 24 or more hours of continuous ambulatory 
ECG monitoring. 
VPS technique. Ventricular fibrillation-flutter was 
initiated in the right ventricle in 16 patients and in 
the left ventricle in two patients. Two extrastimuli 
were required in three patients and three extrasti- 
muli were required in the remaining 15 patients. 
The incidence of VF was similar in patients with and 
without heart disease (7.1% vs 9.6%, N.S.) or 
previous syncope/presyncope (8.8% vs 6.9%) N.S.). 
However, it was significantly higher when VPS 
including three ventricular sites using a current 
strength of 5 mA (pulse width 2 msec) was compared 
to programmed stimulation of two ventricular sites 
using a current twice diastolic threshold (pulse 
width 2 msec) (15.2% vs 3.0%, p < 0.05). 
DISCUSSION 
Prognostic significance. The results of this study 
suggest that VF initiated by VPS in patients with- 
out a documented history of VT or VF has no 
clinical or prognostic significance. The incidence of 
VF was similar in patients with and without struc- 
tural heart disease or previous symptoms of synco- 
pe/presyncope. Regardless of whether or not antiar- 
rhythmic therapy was given, neither cardiac arrest 
nor sudden death occurred in any patient during the 
follow-up period. 
In contrast to the findings of Spielman et al.,6 the 
clinical course subsequent to VPS in our study was 
not ominous for patients in whom VF was initiated. 
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This difference in clinical outcome may be due to 
the differences between the patient groups in the 
two studies. In the study of Spielman et al.,fi all 
patients in whom VF was initiated by VPS had had 
a previously documented or suspected episode of 
sustained VT or a cardiac arrest during which VT or 
VF was documented. Our study was limited only to 
patients without a documented history of sustained 
VT or VF. 
Nonspecific finding. The results of this study sug- 
gest that the initiation of VF by VPS may be a 
nonspecific finding in patients with a prior history of 
syncope. The induction of sustained unimorphic 
VT has been reported to have high diagnostic value 
in patients with unexplained syncope. Treatment 
aimed at suppression of unimorphic VT results in a 
high remission rate of syncope.‘” In contrast, the 
results of this study suggest that VF has no clinical 
significance when it is initiated in patients with 
unexplained syncope. 
In survivors of cardiac arrest, the incidence of 
inducible sustained, unimorphic VT is quite high 
(36% to 53 % ), whereas the incidence of induced VF 
is low (6.5% to 12%j).8-1fl Ambulatory ECG record- 
ings of episodes of sudden death have demonstrated 
that VF is invariably preceded by unimorphic 
VT.‘“, l4 These findings suggest that VF induction by 
VPS in survivors of a cardiac arrest may a nonspe- 
cific finding as well. 
The incidence of VF was increased when a higher 
current strength was used during VPS. Hamer, et 
a1.,15 observed a similar finding in normal canine 
hearts. However, increased current strength alone 
may not have accounted for the incidence of VF in 
our study. A greater number of ventricular sites were 
stimulated when the current strength was increased 
to 5 mA. Although the VPS protocol in our study did 
not allow independent analysis of the importance of 
multiple extrastimuli or ventricular sites, others 
have found these factors to be significant in increas- 
ing the incidence of VF during VPS.i,ls,‘fi 
Limitations. There are several limitations in our 
study. (1) Myocardial biopsy was not performed in 
the eight patients who did not have clinical evidence 
of structural heart disease; therefore, the possibility 
of occult myocardial disease cannot be excluded. (2) 
Because of contraindications, not all patients under- 
went left ventricular stimulation; this may have 
resulted in an underestimation of the incidence of 
VF during VPS. (3) Ventricular programmed stimu- 
lation was terminated when nonsustained, rapid, 
polymorphous VT or nonsustained VF was repro- 
ducibly induced. Continuation of VPS may have 
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resulted in a high incidence of sustained VF. (4) 
Nine of 18 patients in whom VF was initiated by 
VPS were treated with antiarrhythmic agents. We 
cannot exclude the possibility that their benign 
course was due to antiarrhythmic therapy. 
Conclusion. VF initiated by VPS appears to be a 
nonspecific finding in patients who have not previ- 
ously had sustained VT or VF, and does not man- 
date antiarrhythmic therapy. 
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Determinants of simultaneous fast and slow 
pathway conduction in patients with dual 
atrioventricular nodal pathways 
Double His bundle and ventricular responses to a single atrial impulse caused by a simultaneous 
fast and slow pathway conduction was observed during electrophysiologic study in three 
patients with dual-pathway atrioventricular nodal reentrant paroxysmal supraventricular 
tachycardia. In patient No. 1 this phenomenon occurred during rapid atrial pacing, in patient No. 
2 during both rapid atrial pacing and delivery of a single atrial extrastimulus, and in patient No. 3 
during delivery of double atrial extrastimuli. Retrograde unidirectional block in the slow pathway 
was suggested by retrograde induction of tachycardia at a long ventricular paced cycle length 
and/or long ventricular coupling interval In all three patients. Our findings suggest that major 
determinants of this phenomenon include: (1) a sufficient conduction delay in the slow pathway 
so that the distal tissue is able to respond for the second time, and (2) a retrograde 
unidirectional block in the slow pathway so that the fast pathway impulse will not enter and 
collide with the oncoming slow pathway impulse. (AM HEART J lOg:g63, 1985.) 
Fun-Chung Lin, M.D., San-Jou Yeh, M.D., and Delon Wu, M.D. 
Taipei, Taiwan, Republic of China 
In 1975, Wu et al.‘j2 described a patient with double 
His bundle and ventricular responses, as well as a 
patient with pseudoshortening of atrioventricular 
(AV) nodal conduction time (AH interval), caused 
by simultaneous fast and slow AV nodal pathway 
conduction. Subsequently, Gomes et a1.3 observed 
simultaneous fast and slow AV nodal pathway con- 
duction after the administration of procainamide in 
three patients with paroxysmal supraventricular 
tachycardia (PSVT).” In these patients, simulta- 
neous fast and slow pathway conduction was noted 
only during rapid atria1 pacing but not with atrial 
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premature stimulation. Csapo4 reported one patient 
and Sutton and Lee5 reported two patients with a 
complicated form of nonreentrant supraventricular 
tachycardia resulting from simultaneous fast and 
slow AV nodal pathway conduction during sinus 
rhythm. Because of the rarity of this phenomenon, 
its electrophysiologic mechanisms have not been 
completely elucidated. In this study, we describe 
three additional patients with simultaneous fast and 
slow AV nodal pathway conduction and further 
delineate the electrophysiologic determinants of this 
phenomenon. 
METHODS 
Electrophysiologic study. Electrophysiologic study 
was performed in the postabsorptive, nonsedated state 
after informed written consent was obtained. All cardiac 
medication was discontinued at least five half-lives before 
the study. A No. 7 quadripolar electrocatheter (USC1 
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